Premium Nahrungsergänzungsmittel | artgerecht

FIB-4 Index: Estimating Liver Fibrosis Simply

The FIB-4 Index is a non-invasive blood test used to estimate the degree of liver fibrosis. It is calculated from age, platelet count, and two liver enzymes.

Regular tips about health Regular tips about health

Things worth knowing about "FIB-4 Index"

The FIB-4 Index is a non-invasive blood test used to estimate the degree of liver fibrosis. It is calculated from age, platelet count, and two liver enzymes.

What Is the FIB-4 Index?

The FIB-4 Index (Fibrosis-4 Index) is a simple, non-invasive diagnostic score used to estimate the degree of liver fibrosis – the scarring of liver tissue caused by chronic inflammation or injury. The FIB-4 Index is particularly valuable because it requires no liver biopsy and is based entirely on routine blood test values.

Originally developed for patients with chronic hepatitis C, the score is now widely used across various liver conditions, including non-alcoholic fatty liver disease (NAFLD/MASLD) and alcoholic liver disease.

How Is the FIB-4 Index Calculated?

The FIB-4 Index is calculated using a defined formula that incorporates the following parameters:

Age of the patient (in years)
AST (Aspartate Aminotransferase) – a liver enzyme (in U/L)
Platelet count (in 10&sup9;/L)
ALT (Alanine Aminotransferase) – another liver enzyme (in U/L)

The formula is:

FIB-4 = (Age × AST) / (Platelets × √ALT)

All required values are part of a standard blood panel and are routinely measured in clinical practice.

Interpreting the Results

The FIB-4 Index is interpreted using established cut-off values, which may vary slightly between guidelines:

FIB-4 < 1.30: Low risk for advanced fibrosis (F0–F1). Significant liver scarring is unlikely.
FIB-4 1.30 – 2.67: Indeterminate zone – further testing is recommended (e.g., elastography or liver biopsy).
FIB-4 > 2.67: High risk for advanced fibrosis or cirrhosis (F3–F4). Urgent further evaluation is indicated.

In older patients (aged 65 and above), adjusted cut-off values should be applied, as age directly influences the score and may otherwise overestimate the degree of fibrosis.

Clinical Applications

The FIB-4 Index is used across various clinical settings:

Chronic hepatitis B and C: First-line screening tool for fibrosis staging
NAFLD/MASLD and NASH/MASH: Risk stratification in fatty liver disease
Alcoholic liver disease: Monitoring of disease progression and treatment response
General and internal medicine: Cost-effective screening in everyday clinical practice

Advantages and Limitations of the FIB-4 Index

Advantages

Non-invasive: no biopsy required
Cost-effective: based on standard laboratory values
Rapid availability: no specialized equipment needed
Well-validated across diverse patient populations
Recommended in international clinical guidelines (e.g., EASL, AASLD)

Limitations

Results may be influenced by other conditions (e.g., muscle disease, hemolysis)
Indeterminate results require additional diagnostic workup
Age-related adjustments are necessary in elderly patients
Cannot replace liver biopsy in ambiguous cases

FIB-4 Compared to Other Fibrosis Scores

Several other non-invasive scores are available for liver fibrosis assessment:

APRI Score (AST-to-Platelet Ratio Index): simpler but generally less accurate than FIB-4
NFS (NAFLD Fibrosis Score): specifically developed for NAFLD, incorporates additional parameters such as BMI and blood glucose
ELF Test (Enhanced Liver Fibrosis Test): serum marker-based test, more expensive but with higher precision
Liver biopsy: gold standard for fibrosis diagnosis, but invasive

Studies consistently show that the FIB-4 Index is one of the most reliable and cost-effective methods for initial fibrosis screening.

References

Sterling RK et al. - Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006; 43(6):1317–1325.
European Association for the Study of the Liver (EASL) - EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology, 2021; 75(3):659–689.
Castera L et al. - Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019; 156(5):1264–1281.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.